Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Entera bio ltd. save search
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Published: 2021-10-06 (Crawled : 14:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.44%
H: 2.39%
C: -2.61%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.25%
H: 0.36%
C: -0.63%
phase 2 bone positive conference
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
Published: 2021-08-02 (Crawled : 13:15) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 5.4%
H: 2.66%
C: 1.71%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.37%
H: 0.15%
C: -0.96%
treatment phase 2 bone eb613 research osteoporosis
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research
Published: 2021-02-25 (Crawled : 14:01) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: -1.72%
H: 3.51%
C: 3.51%
phase 2 research
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.